Immunotherapy Administered Under the Tongue to Treat Dust Mite Allergy
| Status: | Completed |
|---|---|
| Conditions: | Asthma, Asthma |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 50 |
| Updated: | 5/14/2016 |
| Start Date: | January 2006 |
| End Date: | October 2008 |
Sublingual Immunotherapy in Dust Mite Allergy
This study will investigate sublingual immunotherapy (SLIT), a treatment involving antigens
placement under the tongue to help asthma sufferers build a tolerance to the allergy-causing
substances. Specifically, this study will determine the effectiveness of SLIT at two
different dosing regimens for patients with intermittent mild asthma caused by dust mites.
placement under the tongue to help asthma sufferers build a tolerance to the allergy-causing
substances. Specifically, this study will determine the effectiveness of SLIT at two
different dosing regimens for patients with intermittent mild asthma caused by dust mites.
Asthma is a serious lung condition that is the leading cause of long-term illness in
children. Many common household substances can trigger or worsen an asthma attack. It is
important for people to reduce household allergens and learn effective treatments for
specific types of asthma. Inhaled short-acting beta agonist such as albuterol is the
standard treatment for mild, intermittent asthma. However, recent studies have shown that
adding allergen-specific immunotherapy to your current asthma therapy can help to control
asthma symptoms. This study will determine the safety and effectiveness of SLIT in two
different dosing regimens in treating patients with house dust mite-induced allergic
rhinitis/mild intermittent asthma.
Participants will be randomly assigned to receive low dose SLIT, high dose SLIT, or placebo
for at least 12 months. House dsut mite-induced allergy skin tests will be performed at
study entry, at selected timepoints throughout the study, and at the end of the study. The
tests will determine whether SLIT creates an immune tolerance state as well as whether SLIT
acts via local or systemic immunological systems.
children. Many common household substances can trigger or worsen an asthma attack. It is
important for people to reduce household allergens and learn effective treatments for
specific types of asthma. Inhaled short-acting beta agonist such as albuterol is the
standard treatment for mild, intermittent asthma. However, recent studies have shown that
adding allergen-specific immunotherapy to your current asthma therapy can help to control
asthma symptoms. This study will determine the safety and effectiveness of SLIT in two
different dosing regimens in treating patients with house dust mite-induced allergic
rhinitis/mild intermittent asthma.
Participants will be randomly assigned to receive low dose SLIT, high dose SLIT, or placebo
for at least 12 months. House dsut mite-induced allergy skin tests will be performed at
study entry, at selected timepoints throughout the study, and at the end of the study. The
tests will determine whether SLIT creates an immune tolerance state as well as whether SLIT
acts via local or systemic immunological systems.
Inclusion Criteria:
- House dust mite-induced allergic rhinitis/mild intermittent asthma
Exclusion Criteria:
- Use of previous allergy immunotherapy for house dust mite asthma
- Pregnancy or breastfeeding
We found this trial at
1
site
Click here to add this to my saved trials
